

Expertise Makes It
Possible

Media Center > Events

Wanhuida Partner speaks at 2024 GIPC in Guangzhou

Time: Sept 28 2024

@Wanhuida Intellectual Property

www.wanhuida.com

Expertise Makes It Possible

Wanhuida Partner speaks at 2024 GIPC in Guangzhou

Media Center > Events

On September 28, 2024, the “2024 Global Intellectual Property Conference of Biotech and Pharmaceutical”, which is jointly organized by the IPR Daily and IPR Daily Global, is convened in Guangzhou.

The event features thought-provoking discussions on hot-button issues surrounding policy research, IP enforcement, strategy over litigation and building patent portfolio, and technology commercialization in pharmaceutical and healthcare industry. As usual, the conference is divided into “BioPharma” and “Medical Instrument” forums, featuring 11 keynote speeches, 2 roundtable discussions and 1 closed session.



The conference kicks off with the opening remarks of Zhou Pengzhi, Founder and CEO of IPR Daily. Lei Xiaoyun, Vice President and Associate Secretary General of Patent Protection Association of China, Yi Zhaohui, Researcher, Guangzhou Municipal Administration for Market Regulation (Guangzhou Intellectual Property Office) as well as Tian Shuai, Associate Director of Huangpu District Intellectual Property Office deliver welcome remarks.

Xie Minnan, Partner of Wanhuida Intellectual Property, speaks on “*Formulating Patent Strategy and Building Oversea Patent Portfolio in BioPharma Industry*”. Minnan delves into the comparison between Chinese and foreign patent prosecution regimes and the best practice in utilizing and maximizing the value of foreign patent regime from a case law perspective.

Time: Sept 28 2024

Media Center > Events



Xie Minnan

In the ensuing roundtable discussion, Minnan and her fellow panelists share insights on “*Global BioPharma Intellectual Property Cooperation and Competition*”. Their discussion touches on a plethora of issues including formulation and execution of corporate IP strategy, utilization of patent intelligence, early warning analysis, among others.



Minnan is also included in the “Outstanding Intellectual Property Talent of Pharmaceutical & Healthcare Industry” for her expertise and strong track record in the area.



Xie Minnan (R3)